Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Ítems similars

• Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
  per: Levy, Howard, et al.
  Publicat: (2005)
• Clinical trials in severe sepsis with drotrecogin alfa (activated)
  per: Laterre, Pierre-François
  Publicat: (2007)
• The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  per: Vincent, J, et al.
  Publicat: (2004)
• Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
  per: Beale, R, et al.
  Publicat: (2007)
• Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  per: Vincent, J, et al.
  Publicat: (2004)